SEC Form 4 · accession 0001161697-17-000481
CATALYST PHARMACEUTICALS, INC. · CPRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Patrick J McEnany
Officer — President and CEO · Director
Period of report
Nov 6, 2017
Accepted (ET)
Nov 7, 2017 · 5:13 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001369568
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stock, par value $0.001 per share | Nov 6, 2017 | M | 200,000 | $0.47 | A | 4,671,026 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to purchase common stockF1 | $0.47 | Nov 6, 2017 | M | 200,000 | D | — | Dec 12, 2017 | Common Stock | 200,000 | 500,000 | D |
Explanation of responses
- F1The option was granted on December 12, 2012 and previously vested in three equal annual installments.